In the present investigation, the key intermediate acetohydrazide derivative 5 was synthesized starting from 3-(4-methoxybenzyl)-4-amino-4,5-dihydro-1,2,4-triazol-5-one (1) by a four-step reaction. Thiosemicarbazides 6a-f and arylidenehydrazide derivatives 8a-d were obtained from compound 5. The cyclization of compounds 6a-f in the presence of NaOH resulted in the formation of compounds 7a-f. The compounds were characterized by IR, 1 H NMR, 13 C NMR spectroscopy, elemental analysis and mass spectral studies. The compounds were tested for their anti-lipase, anti-α-glucosidase and anti-mycobacterial activities. Compounds 6b and 8c exhibited excellent anti-lipase activity, and compound 8d showed excellent anti-α-glucosidase activity. Compounds 3 and 4 exhibited good antituberculosis activity.
Introduction
A recent publication of the World Health Organization (WHO) has shown that worldwide obesity, calculated as body mass index (BMI) by dividing the weight by the square of the height, has inreased drastically [1] . In fact, obesity has more than doubled since 1980 [2] . Obesity is a result of the energy imbalance between energy intake and expenditure, the consumption of unhealty foods and lack of exercise [3] . In 2012, obesity WAs the fifth leading risk of deaths, with at least 2.8 million adulthood deaths [4] . There are now over 1.4 billion adults overweight with women outnumbering men by a ratio 3 to 2 [5] . Obesity can cause many diseases such as hypertension, stroke, sleep apne, non insulin dependent hyperlipidemia, and diabetes mellitus, and also coronary heart diseases and certain types of cancer are attributed to overweight and obesity [6, 7] .
Pancreatic lipase is the main lipid-digesting enzyme that catalyzes the hydrolysis of ester bonds of triacylglycerols to produce free fatty acids, diglycerides, monoglycerides and glycerol [8] . Inhibition of pancreatic lipase is an attractive target for the treatment of obesity [9, 10] . α-Glucosidase is a key enzyme involved in the digestion of dietary carbohydrates in humans [11] . This enzyme hydrolyzes polysaccharides into monosaccharides in the small intestine [12] . Inhibition of this enzyme decreases blood glucose levels by delaying or preventing the digestion and hence absorption [13] . Therefore, α-glucosidase inhibitors are widely used in the treatment of patients with type 2 diabetes and obesity [14] .
According to the WHO reports, another leading health problem around the world is tuberculosis (TB) [15] . Tuberculosis is one of the deadly infectious diseases caused by Mycobacterium tuberculosis, and approximately 2 million people die from this disease each year [16] .
1,2,4-Triazoles and their derivatives are an important class of compounds with a wide spectrum of biological activities including antimicrobial [17] , antifungal [18] , antitubercular [19] , anti-inflammatory [20] , anticancer [21] , antihypertensive [22] , antiviral [23] , antidiabetic [24] , anticonvulsant [25] , antidepressant [26] , hypoglycemic [27] , enzyme inhibitory [28] , and antioxidant activity [29] . In addition to these, various compounds containing a 1,2,4-triazole ring are well known drugs such as anastrozole, letrozole, vorozole (antineoplastics, nonsteroidal competitive aromatase inhibitors), fluconazole, itraconazole, terconazole (antifungal agents), ribavirin (antiviral agent), alprazolam (anxiolytic agent, tranquilizer), estazolam (hypnotic, sedative, tranquilizer), etoperidone (antidepressant), benatradin (diuretic), rizatriptan (antimigraine agent), trapidil (hypotensive), trazodone (antidepressant, anxiolytic, selectively inhibiting central serotonin uptake), triazolam (sedative and hypnotic), rilmazafon (hypnotic, anxiolytic, used in the case of neurotic insomnia), and nefazodone (antidepressant, 5-HT2 Aantagonist) [30 -37] . Similarly, acetohydrazide derivatives have shown significant pharmaceutical potential, possessing antimicrobial, antitumor, anticonvulsant, analgesic, antioxidant, anti-inflammatory, antimalarial, antiparasitic, antihypertensive, and antituberculosis activities [38 -43] . Some present day drugs such as isoniazide and isocarboxazide (antituberculosis), nifuroxazide (intestinal antiseptic), ftivazide (antibacterial), and iproniazide (antidepressant) are examples of potent bioactive molecules possessing hydrazide-hydrazone moieties [44 -47] . Moreover, hydrazide derivatives can be considered as useful intermediates leading to the formation of a wide variety of heterocyclic compounds such as pyrroles, pyrazoles, imidazoles, oxadiazoles, thiadiazoles, and triazoles [48] . On the other hand, 1,2,4-triazoles bearing open-chain thiosemicarbazide and mercapto-1,2,4-triazole moities are also more potent biologically active compounds [49 -51] . In view of these findings, we report the synthesis, characterization, lipase and α-glucosidase inhibitory properties, and anti-mycobacterial activities of some new 2-heptyl-5-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one derivatives.
Results and Discussion

Chemistry
The synthetic route to compounds 1-8 is outlined in Scheme 1. In the present work, 3-(4-methoxybenzyl)-4-amino-4,5-dihydro-1,2,4-triazol-5-one (1) was prepared according to the literature [52] . The reaction of compound 1 with 1-bromoheptane in the presence of sodium ethoxide produced compound 2. The preparation of compound 3 was achieved in good yield by deamination of compound 2 in the presence of hypophosphorous acid (50 % aqueous solution) and sodium nitrite according to the literature [53] . Compound 3 was transformed into the ethyl acetate derivative 4 by reacting it with ethyl bromoacetate in the presence of sodium ethoxide. The key intermediate in our study has been the acetohydrazide derivative 5, which was prepared by the reaction of 4 and hydrazine hydrate in butanol. The condensation of the acid hydrazide 5 with alkyl/aryl isothiocyanates resulted in the formation of thiosemicarbazide derivatives 6a-f. The FT-IR spectra exhibited characteristic absorption bands at 3213 -3275 and 1671 -1678 cm −1 due to three NH and thiosemicarbazide C=O vibrations, respectively. The 1 H NMR signals of the protons linked to N1-N2 and N3 nitrogens appeared at δ = 7.44 -9.82 and 9.80 -10.41 ppm, respectively. The characteristic carbon signals were observed at around δ = 166 (thiosemicarbazide C=O) and 180 ppm (thiosemicarbazide C=S). The synthesized thiosemicarbazides 6a-f were cyclized with 2 M sodium hydroxide in the presence of ethanol to obtain the corresponding derivatives 7a-f. Compounds 7a-f can exist in thiole and thione tautomeric forms [54] . Spectral analysis (IR and 1 H NMR) has shown that these compounds have the thione structure. In the IR spectra, the SH vibration bands (2500 -2600 cm −1 ) were absent and the C=S vibration bands were observed in the region 1314 -1351 cm −1 . Also, the presence of NH absorption bands in the region 3100 -3374 cm −1 and signals at δ = 13.52 -13.85 ppm in the 1 H NMR spectrum are supporting proofs for the formation of the thione tautomeric form [54 -56] .
Compound 5 was condensed with various aromatic aldehydes in ethanol to give the corresponding arylidene hydrazides (8a-d). In the FT-IR spectra of 8a-d, we observed bands at around 3210, 3175 and 1689 cm −1 due to OH, (CO)NH and hydrazide C=O stretching vibrations, respectively. The signals belonging to benzyl CH 2 , NCH 2 C=O, N=CH, OH, and NH groups in the 1 H NMR spectra and to triazole C-3, triazole C=O and N=CH in the 13 C NMR spectra of 8a-d were observed as double singlets. According to the literature, arylidene hydrazide derivatives may exist as E/Z geometrical isomers with respect to the C=N double bonds and as cis/trans amide conformers at the N-C(O) bond [57, 58] . It is known that, when arylidene hydrazide derivatives are dissolved in polar solvents such as dimethyl [D 6 ] sulfoxide, the geometrical E isomers of these compounds undergo a rapid trans/cis amide equilibration, in which the trans conformer predominates [21, 59] . The E isomers and the trans/cis conformer ratios can be calculated from 1 H NMR data [57 -59] . In this study, we determined the percentage ratios of trans/cis in the mixture of the conformers of compounds 8a-d. 
Pharmacology
Anti-lipase activity
All compounds were evaluated with regard to pancreatic lipase activity and 6a-6c, 6e, 8a-8c showed anti-lipase activities at various concentrations (Table 1). No significant inhibitory effect was detected for the other compounds. Among the tested compounds, 8c and 6b showed the best anti-lipase activity. These compounds inhibited pancreatic lipase activity by 98.3 % and 91.5 % at a concentration of 9.375 µ M, respectively (Table 1) . Orlistat, a known pancreatic lipase inhibitor used as an antiobesity drug, showed an inhibitory effect of 95.3 % at a concentration of 312 nM. IC 50 values for compounds 8c and 6b were calculated as 0.04 ± 0.00 and 0.63 ± 0.1 µ M, respectively. The IC 50 value of 8b was determined as 1.13 ± 0.2 µ M. Orlistat is the only approved antiobesity medication [60] , but it has some side effects, such as fecal incontinence, flatulence, and steatorrhea [61, 62] . The synthesized compounds 8c and 6b have a significant potential to become alternatives of Orlistat.
α-Glucosidase inhibitory activity
All compounds were evaluated with regard to their α-glucosidase activity, and 6a-c, 7f and8a-d showed anti-α-glucosidase activity at various concentrations. These compounds exhibited a larger inhibitory effect than Acarbose, a known α-glucosidase inhibitor used as an antidiabetic drug ( Table 2) . No significant inhibitory effect was detected for other compounds. Among the tested compounds, 8d showed the best anti-α-glucosidase activity. The compound inhibited α-glucosidase activity by 100±0.2 % at a concentration of 100 µ M. Acarbose showed an inhibitory effect by 55.4±3.0 % at the same concentration. IC 50 values of Acarbose and compound 8d were calculated as 69.16 ± 5.2 and 0.59 ± 0.02 µ M, respectively ( Table 2) .
Anti-mycobacterial activity
The anti-mycobacterial activity results of the newly synthesized compounds are presented in Table 3 . The compounds not mentioned in Table 3 were found to be ineffective. Compounds 3 and 4 were effective against M. smegmatis (17 and 18 mm inhibition zone, respectively). Besides, compounds 2, 6f and 7d showed a moderate effect against M. smegmatis. The other compounds exhibited only weak effects (7 -9 mm inhibition zone).
Conclusion
One of the current antiobesity strategies is the inhibition of the digestive enzymes lipase and glycosidase with the use of inhibitors orlistat and acarbose, respectively. However, these and other drugs available in the market have limitations and produce serious side effects [60 -63] . Mycobacterium tuberculosis is the cause of tuberculosis, and currently the antibiotics including isoniazid, rifampicin, pyrazinamide, ethambutol and streptomycin are used as antituberculosis agents. The effectiveness of these drugs is severely compromised because extensive drugresistant tuberculosis (MDR-TB and XDR-TB) has emerged [64 -66] .
As the current antiobesity and antituberculosis drugs have limitations and side-effects, new drugs or leads are required to combat pathologies and infections. Thus, new acetohydrazide (5), open-chain thiosemicarbazides (6a-f), 1,2,4-triazole-5-thiones (7a-f), and benzylidene hydrazides (8a-d) bearing a 2-heptyl-5-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one ring have been synthesized.
Among the tested compounds, 8c (0.04 ± 0.00 µ M) and 6b (0.63 ± 0.1 µ M) showed a high anti-lipase activity, 8d (0.59 ± 0.02 µ M) showed a high anti-α-glucosidase activity, and compounds 3 and 4 were effective against M. smegmatis (17 and 18 mm inhibition zones, respectively). In addition, compounds 2, 6f and 7d showed moderate effects against M. smegmatis. The structures of the active compounds are clearly unrelated with those currently in clinical use, and deserve further investigations.
Experimental Section
Chemistry
All melting points were determined on a Gallenkamp Electrothermal digital melting point apparatus. Infrared (IR) spectra were recorded with a Perkin-Elmer Frontier FT-IR spectrophotometer using attenuated total reflection (ATR) accessory. 1 H and 13 C NMR spectra were recorded in [D 6 ]DMSO on a Varian Mercury 400 MHz spectrometer using TMS as internal standard. The elemental analyses were performed on a Costech Elemental Combustion System CHNS-O elemental analyzer. Mass spectra were measured on a Quattro LC-MS (70 eV) 4.0 micromass spectrometer.
The reactions were monitored by thin layer chromatography (TLC) using 0.2 mm precoated plates of silica gel G60 F254. Compound 1 was synthesized by the method reported earlier [52] .
General method for the synthesis of compounds 2 and 4
The corresponding compound 1 (10 mmol) was refluxed with 1 equivalent of sodium in absolute ethanol for 2 h. Then, 1-bromoheptane-ethyl bromoacetate (10 mmol) was added, and the mixture was refluxed for additional 8 h. After evaporation of the solvent under reduced pressure, a solid appeared, which was recrystallized from ethanol-water (1 : 2) to afford the desired products. (17) . 5-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (3) To a mixture of compound 2 (0.01 mol) with an aqueous solution of 50 % hypophosphorous acid (30 mL), an aqueous solution of sodium nitrite (0.05 mol in 10 mL of water) was added slowly. Vigorous nitrogen evolution was observed during this addition, and the mixture was stirred at room temperature for 1 h. The precipitate formed was filtred, washed with water and recrystallized from ethanol-water (1 : 1 (38) .
4-Amino-2-heptyl-5-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (2)
M. p. 98 -99
Synthesis of 2-heptyl-
Synthesis of 2-[1-heptyl-3-(4-methoxybenzyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl] acetohydrazide (5)
Compound 4 (0.01 mol) and hydrazine hydrate (0.025 mol) in n-butanol (25 mL) were refluxed for 6 h. After cooling to room temperature, a colorless solid appeared. The solid mass that separated was filtered, dried and recrystallized from ethanol to get the desired product as a solid. (12) .
General method for the synthesis of compounds 6a-f
A mixture of an acid hydrazide 5 (0.01 mol) and an alkyl/aryl isothiocynate (0.01 mol) was refluxed in absolute ethanol for 3 -5 h. The solution was cooled and a colorless solid appeared. This was filtered and recrystallized from ethanol. (54) .
2-{[1-Heptyl-3-(4-methoxybenzyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetyl}-4-methylthiosemicarbazide (6a)
M
2-{[1-Heptyl-3-(4-methoxybenzyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetyl}-4-ethylthiosemicarbazide (6b)
2-{[1-Heptyl-3-(4-methoxybenzyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetyl}-4-phenylthiosemicarbazide (6c)
2-{[1-Heptyl-3-(4-methoxybenzyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetyl}-4-(4-fluorophenyl)-thiosemicarbazide (6d)
2-{[1-Heptyl-3-(4-methoxybenzyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]acetyl}-4-(4-chlorophenyl)-thiosemicarbazide (6e)
General method for the synthesis of compounds 7a-f
A 20 mL ethanolic solution of a thiosemicarbazide 6a-f (0.01 mol) was refluxed in aqueous NaOH solution (2 M, 50 mL). The reaction was monitored by TLC. After completion of the reaction (4 -6 h), the reaction mixture was cooled and then acidified to pH = 3 -4 with concentrated HCl. The precipitate formed was filtered, washed with cold water and recrystallized from ethanol-water (1:1). 
2-Heptyl-4-[(4-methyl-4,5-dihydro-5-thione-1H-1,2,4-triazol-3-yl)methyl]-5-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (7a)
2-Heptyl-4-[(4-phenyl-4,5-dihydro-5-thione-1H-1,2,4-triazol-3-yl)methyl]-5-(4-methoxybenzyl)-2,4-dihydro-3H-1,2,4-triazol-3-one (7c)
hyde (0.01 mol) for 2 h. After 1 h, the crude product precipitated from the reaction medium. It was recrystallized from ethanol.
2-[3-(4-Methoxybenzyl)-1-heptyl-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N -[(2-hydroxyphenyl)methylidene]-acetohydrazide (8a)
The inhibitory effects of the compounds were evaluated against Porcine Pancreatic Lipase (obtained from Applichem, Germany) (15 ng mL −1 ). Lipase activity assays were performed according to Kurihara et al. [67] . The lipase activity was measured using 4-methylumbelliferyl oleate (4-MU oleate) as a substrate. Briefly, compounds were mixed with PPL 1 : 3 (v/v) and incubated for 30 min. The microtiter plates containing 50 µL 0.1 mM 4-MU oleate, 25 µL diluted compound-lipase solution, 25 µL H 2 O and assay buffer (13 mM Tris-HCl, 150 mM NaCl, and 1.3 mM CaCl 2 , pH = 8.0) were incubated at 37 • C for 20 min. After incubation, in order to stop the reaction, 0.1 mL 0.1 M citrate buffer was added to the reaction mixture. The amount of 4-methylumbelliferone released by the lipase was measured by using a spectrofluorometer (SpectraMax M5, Molecular Devices) at an excitation wavelength of 355 nm and an emission wavelength of 460 nm. The inhibitory activity of these compounds and Orlistat (Xenical, Hoffman, La Roche, Segrate, Italy), an inhibitor control of pancreatic lipase, were measured at various concentration. Residual activities were calculated by comparing to a control without inhibitor. The assays were done in triplicate. The IC 50 values were determined as the concentration of a compound that gave 50 % inhibition of maximal activity.
α-Glucosidase inhibition assay
The α-glucosidase inhibition assay was performed spectrophotometrically. α-Glucosidase from Saccharomyces cerevisiae (Sigma-Aldrich) was dissolved in phosphate buffer (pH = 6.8, 50 mM). The test compounds were dissolved in 80 % methanol. In 96-well microtiter plates, 20 µL of the test sample, 20 µL of the enzyme (200 mU mL −1 ) and 135 µL of the buffer were added and incubated for 15 min at 37 • C. After incubation, 25 µL of p-nitrophenyl-α-Dglucopyranoside (2 mM, Sigma-Aldrich) was added, and the change in absorbance was monitored for 30 min at 400 nm. The test compound was replaced by 80 % methanol (7.5 % final concentration) as control. Acarbose (Sigma-Aldrich) was used as a standard inhibitor [68] .
Anti-mycobacterial activity assay
Mycobacterium smegmatis ATCC 607 was obtained from the Hifzissihha Institute of Refik Saydam (Ankara, Turkey). All compounds were weighed and dissolved in dimethyl sulfoxide (DMSO) to prepare an extract stock solution of 20 mM. The anti-mycobacterial assay was performed in Brain Heart Infusion broth (BHI) (Difco, Detriot, MI). Streptomycin (10 µg) was used as standard anti-mycobacterial drug. DMSO was used as solvent control. Five-millimeter diameter wells were cut from the agar using a sterile corkborer, and 50 µL of the compound was delivered into the wells. The petri dishes were incubated for 48 -72 h at 35 • C [69] . Anti-mycobacterial activity was evaluated by measuring the inhibition zone against the test organism. The test was done in duplicate.
